Moderna, AstraZeneca heart drug succeeds early-stage trial

Published On 2017-09-17 03:45 GMT   |   Update On 2017-09-17 03:45 GMT

Biotech unicorn Moderna Therapeutics said on Thursday its heart drug, developed along with British drugmaker AstraZeneca met the main goal in an early-stage trial.


The company, which develops drugs based on a molecule known as messenger RNA, said AstraZeneca has submitted a clinical trial application in Europe for a mid-stage study of the drug, mRNA AZD-8601, in patients undergoing coronary artery bypass grafting (CABG) surgery.


Messenger RNA (mRNA) carries the recipe for making proteins inside the body. Using it as a medicine could offer a new way to tackle many hard-to-treat diseases, from cancer to infections to heart and kidney disorders.


AstraZeneca first invested $240 million in 2013 to access Moderna's know-how in manipulating RNA, or ribonucleic acid, which helps create proteins inside cells - another example of CEO Pascal Soriot placing a bet on new science.


In 2016, AstraZeneca invested another $140 million in Moderna, which already has a cash pile of around $1 billion.


(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Arun Koyyur)

Article Source : REUTERS

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News